Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 2089710

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2089710

Psoriasis Drugs Market Size, Share & Trends Analysis Report By Class, By Treatment, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Psoriasis Drugs Market Summary

The global psoriasis drugs market size was valued at USD 23.27 billion in 2025 and is projected to grow from USD 25.70 billion in 2026 to USD 54.88 billion by 2033, at a CAGR of 11.4% from 2026 to 2033. North America psoriasis drugs market held the largest share of 38.3% of the global market in 2025. The psoriasis drugs market is witnessing strong growth driven by advances in immunomodulators, increasing adoption of biologic therapies, and favorable reimbursement support across developed healthcare markets.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

Continuous research and development activities are contributing to treatment innovation, particularly for moderate to severe psoriasis cases, thereby supporting demand for targeted therapies. A major market trend is the increasing competition from biosimilars, which is reshaping the competitive landscape for established biologics and improving treatment accessibility. Growing acceptance of biosimilars among healthcare providers and payers is helping reduce herapy costs and expand patient access, especially in cost-sensitive markets. In addition, the market continues to shift toward advanced interleukin inhibitors and targeted oral therapies due to their improved efficacy, longer treatment durability, and favorable clinical outcomes compared to conventional systemic treatments.The market is also experiencing a strong shift toward precision-based psoriasis management, supported by the increasing preference for targeted biologics and next-generation oral therapies. Interleukin inhibitors targeting IL-17 and IL-23 pathways continue to gain significant commercial traction due to their high skin clearance rates, rapid onset of action, and sustained therapeutic response. Pharmaceutical companies are actively focusing on lifecycle management strategies, label expansions, and development of improved formulations to strengthen product positioning in the competitive immunology segment. In addition, increasing physician awareness regarding long-term disease management and comorbidity reduction is contributing to higher adoption of advanced psoriasis therapeutics.

Rising prevalence of chronic inflammatory skin disorders and increasing demand for long-term disease management therapies continue to support the growth of the psoriasis drugs market. The market is benefiting from higher adoption of advanced biologics and targeted therapies that offer improved efficacy, better symptom control, and enhanced patient outcomes compared to conventional treatments. In addition, increasing healthcare expenditure, expanding access to specialty dermatology care, and growing awareness regarding early diagnosis and treatment are further contributing to market expansion. Continuous product innovation, broader biosimilar availability, and ongoing regulatory support for novel psoriasis therapies are expected to sustain competitive development and create favorable growth opportunities for the market during the forecast period.

Global Psoriasis Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psoriasis drugs market report based on class, treatment, route of administration, distribution channel, and region:

  • Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Tumor Necrosis Factor Inhibitors
  • Interleukin Inhibitors
  • Vitamin D Analogues
  • Corticosteroids
  • Others
  • Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
  • Topicals
  • Systemic
  • Biologics
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Parenteral
  • Topical
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Pharmacies
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Product Code: GVR-1-68038-662-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Class
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Psoriasis Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Psoriasis Drugs Market: Class Business Analysis

  • 4.1. Class Market Share, 2025 & 2033
  • 4.2. Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Class, 2021 to 2033 (USD Billion)
  • 4.4. Tumor Necrosis Factor Inhibitors
    • 4.4.1. Tumor Necrosis Factor Inhibitors Market, 2021 - 2033 (USD Billion)
  • 4.5. Interleukin Inhibitors
    • 4.5.1. Interleukin Inhibitors Market, 2021 - 2033 (USD Billion)
  • 4.6. Vitamin D Analogues
    • 4.6.1. Vitamin D Analogues Market, 2021 - 2033 (USD Billion)
  • 4.7. Corticosteroids
    • 4.7.1. Corticosteroids Market, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Psoriasis Drugs Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
  • 5.4. Topicals
    • 5.4.1. Topicals Market, 2021 - 2033 (USD Billion)
  • 5.5. Systemic
    • 5.5.1. Systemic Market, 2021 - 2033 (USD Billion)
  • 5.6. Biologics
    • 5.6.1. Biologics Market, 2021 - 2033 (USD Billion)

Chapter 6. Psoriasis Drugs Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
  • 6.5. Parenteral
    • 6.5.1. Parenteral Market, 2021 - 2033 (USD Billion)
  • 6.6. Topical
    • 6.6.1. Topical Market, 2021 - 2033 (USD Billion)

Chapter 7. Psoriasis Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.6. Other Pharmacies
    • 7.6.1. Other Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 8. Psoriasis Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 8.4. North America
    • 8.4.1. North America Psoriasis Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. AbbVie Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Amgen Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Johnson & Johnson Services, Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Novartis AG
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Eli Lilly And Company
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Celgene Corporation
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. UCB S.A.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Merck
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Boehringer Ingelheim International GmbH
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
Product Code: GVR-1-68038-662-2

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global psoriasis drugs market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 5 Global psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 6 Global psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 7 Global psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 8 North America psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 9 North America psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 10 North America psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 11 North America psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 12 North America psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 13 U.S psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 14 U.S psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 15 U.S psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 16 U.S psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Canada psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 18 Canada psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 19 Canada psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 20 Canada psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 21 Mexico psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 22 Mexico psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 23 Mexico psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 24 Mexico psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 25 Europe psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 26 Europe psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 27 Europe psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 28 Europe psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 29 Europe psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 UK psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 31 UK psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 32 UK psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 33 UK psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 34 Germany psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 35 Germany psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 36 Germany psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 37 Germany psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 38 France psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 39 France psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 40 France psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 41 France psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Italy psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 43 Italy psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 44 Italy psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 45 Italy psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 46 Spain psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 47 Spain psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 48 Spain psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 49 Spain psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 50 Norway psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 51 Norway psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 52 Norway psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 53 Norway psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 54 Denmark psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 55 Denmark psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 56 Denmark psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 57 Denmark psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 Sweden psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 59 Sweden psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 60 Sweden psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 61 Sweden psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Japan psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 68 Japan psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 69 Japan psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 70 Japan psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 71 China psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 72 China psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 73 China psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 74 China psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 75 India psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 76 India psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 77 India psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 78 India psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 79 Australia psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 80 Australia psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 81 Australia psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 82 Australia psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 83 South Korea psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 84 South Korea psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 85 South Korea psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 86 South Korea psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Thailand psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 88 Thailand psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 89 Thailand psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 90 Thailand psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 91 Latin America psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 93 Latin America psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 94 Latin America psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 95 Latin America psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 96 Brazil psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 97 Brazil psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 98 Brazil psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 99 Brazil psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 100 Argentina psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 101 Argentina psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 102 Argentina psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 103 Argentina psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 109 South Africa psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 110 South Africa psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 111 South Africa psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 112 South Africa psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 117 UAE psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 118 UAE psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 119 UAE psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 120 UAE psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Psoriasis drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Psoriasis drugs market dynamics
  • Fig. 11 Psoriasis drugs market: Porter's five forces analysis
  • Fig. 12 Psoriasis drugs market: PESTLE analysis
  • Fig. 13 Class market, 2021 - 2033 (USD Billion)
  • Fig. 14 Tumor necrosis factor inhibitors market, 2021 - 2033 (USD Billion)
  • Fig. 15 Interleukin inhibitors market, 2021 - 2033 (USD Billion)
  • Fig. 16 Vitamin D analogues market, 2021 - 2033 (USD Billion)
  • Fig. 17 Corticosteroids market, 2021 - 2033 (USD Billion)
  • Fig. 18 Others market, 2021 - 2033 (USD Billion)
  • Fig. 19 Treatment market, 2021 - 2033 (USD Billion)
  • Fig. 20 Topicals market, 2021 - 2033 (USD Billion)
  • Fig. 21 Systemic market, 2021 - 2033 (USD Billion)
  • Fig. 22 Biologics market, 2021 - 2033 (USD Billion)
  • Fig. 23 Route of administration market, 2021 - 2033 (USD Billion)
  • Fig. 24 Oral market, 2021 - 2033 (USD Billion)
  • Fig. 25 Parenteral market, 2021 - 2033 (USD Billion)
  • Fig. 26 Topical market, 2021 - 2033 (USD Billion)
  • Fig. 27 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 28 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 29 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 30 Other pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 31 Psoriasis drugs market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 40 Europe Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 57 Asia Pacific Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 70 Latin America Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 75 MEA Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!